Immuron director resignation

Melbourne, australia, sept. 24, 2021 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of mr peter anastasiou.
IMRN Ratings Summary
IMRN Quant Ranking